Overview

This trial is active, not recruiting.

Condition acute myeloid leukemia with flt3 activating mutations that has relapsed or been refractory after one or more prior therapies
Treatment crenolanib besylate
Phase phase 2
Targets PDGF, FLT-3
Sponsor Arog Pharmaceuticals, Inc.
Start date October 2012
End date May 2016
Trial size 70 participants
Trial identifier NCT01657682, ARO-005

Summary

This pilot Phase II study is designed to evaluate the efficacy and tolerability of crenolanib in two cohorts of AML patients with FLT3 activation mutations (patients whose leukemia has recurred after prior chemotherapy not including a FLT3 TKI and patients whose leukemia has progressed after prior therapy with a FLT3 TKI).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Will enroll relapsed/refractory AML patients with FLT3 activating mutations who progressed on one or more prior chemotherapy regimens excluding any FLT3 TKI.
crenolanib besylate
Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule. Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy.
(Experimental)
Will enroll relapsed/refractory AML patients with FLT3 activating mutations whose leukemia has progressed and have history of prior therapy with one or more FLT3 TKIs.
crenolanib besylate
Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule. Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy.

Primary Outcomes

Measure
Response rate of patients receiving crenolanib therapy
time frame: 1 year
Toxicity rate associated with crenolanib therapy
time frame: 1 year

Secondary Outcomes

Measure
Duration of response
time frame: 1 year
Pharmacodynamic markers
time frame: 1 year
Duration of progression-free survival and overall survival
time frame: 1 year
Pharmacokinetic markers
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Confirmed primary AML relapsed or refractory after prior therapy, AML secondary to antecedent chemotherapy or radiation therapy, or AML due to prior myelodysplastic syndrome (MDS)/ myeloproliferative neoplasm (MPN) as defined by WHO criteria with presence of either FLT3 ITD and/or other FLT3 activating mutations - Patients with secondary AML should have failed no more than two (2) prior regimens - Patients with antecedent MDS/MPN, defined by WHO criteria, without any prior therapy for AML, regardless of the number of therapies for MDS/ MPN - Patients with primary AML should have received no more than two (2) prior cytotoxic containing salvage regimens. Reinduction with the same regimen or stem cell transplant will not be considered a separate salvage regimen. Change of drugs will be considered a salvage regimen. Unlimited FLT3 TKI therapy (even in combination with cytotoxics/hypomethylating agents) is allowed for patients enrolled in cohort B - Patients must have tested positive for FLT3-ITD and /or other FLT3 activating mutations within 30 day screening period - Males and females age ≥18 years - ECOG PS 0-2 - Adequate liver function, defined as bilirubin ≤1.5x ULN, ALT ≤3.0x ULN, and AST ≤3.0x ULN - Adequate renal function, defined as serum creatinine ≤1.5x ULN - Recovery from non-hematological toxicities of prior therapy (including HSCT) to no more than grade 1 (except alopecia) - Subjects should have received no anti-leukemic therapy (except hydroxyurea) prior to the first dose of crenolanib as follows: for 14 days for classical cytotoxic agents and for five times the t1/2 (half-life) for FLT3 inhibitors and antineoplastic agents that are neither cytotoxic nor FLT3 inhibitors (e.g. hypomethylating agent or MEK inhibitor) - Negative pregnancy test for WOCBP - Able and willing to provide written informed consent. Exclusion Criteria: - Absence of a FLT3 activating mutation - <5% blasts in blood or marrow at screening - Concurrent chemotherapy, or targeted anti-cancer agents, other than hydroxyurea - Patient with concurrent severe and/or uncontrolled medical conditions that in the opinion of the investigator may impair the participation in the study or the evaluation of safety and/or efficacy - HIV infection or active hepatitis B (defined as hepatitis B surface antigen positive) or C (defined as hepatitis C antibody positive) - Known clinically active central nervous system (CNS) leukemia - Patients less than 30 days post HSCT - Subjects who have clinically significant graft versus host disease requiring treatment and /or have >grade 2 persistent non hematological toxicity related to transplant - Prior crenolanib treatment for a non-leukemic indication - Major surgical procedures within 14 days of Day 1 administration of crenolanib. - Unwillingness or inability to comply with protocol.

Additional Information

Official title A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Description This is a Phase II open label study of crenolanib besylate. This study will enroll subjects with relapsed acute myeloid leukemia (AML) with FLT3 activating mutations. Two cohorts of patients will be enrolled: those whose AML has recurred after prior chemotherapy without a FLT3 TKI, and those whose AML has progressed after prior therapy with FLT3 TKIs. Subjects will take Crenolanib besylate at 100 mg TID until disease progression, death, or unacceptable toxicities. Concurrent hydroxyurea is permitted during the first 28 days of study therapy.
Trial information was received from ClinicalTrials.gov and was last updated in November 2015.
Information provided to ClinicalTrials.gov by Arog Pharmaceuticals, Inc..
Location data was received from the National Cancer Institute and was last updated in April 2016.